SG10201710322VA - Anti-c5 antibodies and methods of use - Google Patents

SE370449B (en) 1970-08-29 1974-10-14 Philips Nv JPS5824836B2 (en) 1974-10-14 1983-05-24 ノウミボウサイコウギヨウ カブシキガイシヤ Kasainadonotsuhousouchi US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations ES8404858A1 (en) 1982-04-12 1984-05-16 Hybritech Inc Method of affinity purification employing monoclonal antibodies. US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies JPS6350741A (en) 1986-08-20 1988-03-03 Nippon Tectron Co Ltd Fluorescent polarization analyser JPH06104071B2 (en) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 Factor IX Monoclonal antibody specific for conformation US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies JPH0636741B2 (en) 1989-11-08 1994-05-18 帝人株式会社 Method for separating human protein C US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice EP0515571B1 (en) 1990-02-16 1998-12-02 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor KR100249937B1 (en) 1991-04-25 2000-04-01 나가야마 오사무 Reconstituted Human Antibody Against Human Interleukin-6 Receptor EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies PT752248E (en) 1992-11-13 2001-01-31 Idec Pharma Corp THERAPEUTIC APPLICATION OF QUIMERIC ANTIBODIES AND RADIOACTIVELY MARKING OF ANTIGENES OF RESTRICTED DIFFERENTIATION OF HUMAN LYMPHOCYTE B FOR THE TREATMENT OF B-CELL LYMPHOMA US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides WO1994029471A1 (en) 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides DK0783893T3 (en) 1994-10-07 2012-05-29 Chugai Pharmaceutical Co Ltd INHIBITION OF ANNORMAL GROWTH OF SYNOVIAL CELLS USING IL-6 ANTAGONIST AS ACTIVE INGREDIENT DE4436561C1 (en) 1994-10-13 1996-03-14 Deutsche Spezialglas Ag Changing curvature of anodically bonded flat composite bodies, e.g. glass and metal RU2147442C1 (en) 1994-10-21 2000-04-20 Кисимото Тадамицу Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies CZ399A3 (en) 1996-07-19 1999-06-16 Amgen Inc. Polypeptide analogs of cation-active polypeptides US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies JP4086908B2 (en) 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド Compositions and methods comprising conjugates of stable and active human OB protein and antibody Fc chains US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation PT994903E (en) 1997-06-24 2005-10-31 Genentech Inc METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed CN1277632A (en) 1997-10-03 2000-12-20 中外制药株式会社 Natural human antibody JP2001521909A (en) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド Methods and compositions comprising glycoprotein glycoforms US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof EP2180007B2 (en) 1998-04-20 2017-08-30 Roche Glycart AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus CN1214043C (en) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 Humanized antibodies to gamma-interferon US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function CN1763097B (en) 1999-01-15 2011-04-13 杰南技术公司 Polypeptide variants with altered effector function US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide SE9903895D0 (en) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor AU6627201A (en) 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity MXPA03002974A (en) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Cells producing antibody compositions. DE60140618D1 (en) 2000-10-10 2010-01-07 Genentech Inc INHIBITION OF C5 COMPLEMENT ACTIVATION FOR THE TREATMENT AND PREVENTION OF XENO TRANSPLANT OR ACUTE VASCULAR EXHAUSTION US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells PT1354034E (en) 2000-11-30 2008-02-28 Medarex Inc Transgenic transchromosomal rodents for making human antibodies EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof EE200300509A (en) 2001-04-13 2004-08-16 Biogen, Inc. Antibodies to VLA-1 US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor EP1411118B1 (en) 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican-3 antibody US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity CN100391537C (en) 2001-08-17 2008-06-04 建南德克公司 Complement pathway inhibitors binding to C5 and C5A without preventing formation of C5B US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof ES2326964T3 (en) 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS. EP1562968B1 (en) 2001-11-14 2013-08-21 Janssen Biotech, Inc. Anti-il-6 antibodies, compositions, methods and uses US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20 US6684637B2 (en) 2002-01-25 2004-02-03 Sunpower, Inc. Parallel slot heat exchanger CA2472922A1 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition JP4628679B2 (en) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Cells in which the activity of a protein involved in GDP-fucose transport is reduced or deleted AU2003236022A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target WO2003107009A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods for improving a binding characteristic of a molecule ITMI20021527A1 (en) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE CA2492524A1 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis RU2326127C2 (en) 2002-12-16 2008-06-10 Джинентех, Инк. Versions of immunoglobulins and its application EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis EP1603936B1 (en) 2003-02-28 2012-04-11 Agenus Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules AU2004215653B2 (en) 2003-02-28 2011-03-17 Lonza Biologics Plc. Antibody purification by protein A and ion exchange chromatography US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders EP1663306A2 (en) 2003-09-05 2006-06-07 Genentech, Inc. Antibodies with altered effector functions CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein ES2550311T3 (en) 2003-11-05 2015-11-06 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function ES2285543T3 (en) 2003-11-05 2007-11-16 Ares Trading S.A. PROCEDURE FOR THE PURIFICATION OF PROTEIN FROM UNION TO IL-18. BR122018071968B8 (en) 2003-11-06 2021-07-27 Seattle Genetics Inc antibody-drug conjugate, pharmaceutical composition, article of manufacture and use of an antibody-drug conjugate CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition SI2418220T1 (en) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses PA8621301A1 (en) 2004-01-09 2006-09-22 Pfizer ANTIBODIES AGAINST MAdCAM US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia CA2555688C (en) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids KR101245983B1 (en) 2004-03-31 2013-06-28 제넨테크, 인크. Humanized anti-TGF-beta antibodies US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them KR100620554B1 (en) 2004-06-05 2006-09-06 한국생명공학연구원 Humanized antibody against TA-72 AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME CN102532321B (en) 2004-06-18 2018-10-12 Ambrx公司 Novel antigen-binding polypeptides and its purposes CA2572133A1 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants BRPI0514068B8 (en) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anti-cd20 antibody, and, pharmaceutical composition CA2579142A1 (en) 2004-09-13 2006-03-23 Macrogenics, Inc. Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof EP1799718A1 (en) 2004-09-14 2007-06-27 National Institute for Biological Standards and Control (NIBSC) Vaccine US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations. US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn WO2006067847A1 (en) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha Method of preparing antibody by use of cell having its fucose transporter function inhibited DE602005020061D1 (en) 2004-12-23 2010-04-29 Novo Nordisk As LIGANDS WITH ANTIBODY-BINDING AFFINITY GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds DK3050963T3 (en) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control EP1876236B9 (en) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease MX2008002367A (en) 2005-08-19 2008-03-18 Wyeth Corp Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders. EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences ES2551604T3 (en) * 2005-12-12 2015-11-20 Ac Immune S.A. Therapeutic vaccine UA101301C2 (en) 2005-12-29 2013-03-25 Сентокор, Инк. Isolated il-23pl9 antibody and use thereof PT1988882E (en) 2006-03-02 2015-02-17 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity EP4159220A1 (en) 2006-03-08 2023-04-05 Archemix LLC Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody AU2007235484B2 (en) 2006-04-05 2013-11-07 Abbvie Biotechnology Ltd Antibody purification EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds KR20150091545A (en) 2006-06-08 2015-08-11 추가이 세이야쿠 가부시키가이샤 Preventive or remedy for inflammatory disease WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies CA2665287C (en) 2006-10-06 2022-08-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof JP2010521194A (en) * 2007-03-22 2010-06-24 ノバルティス アーゲー C5 antigen and uses thereof CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method JP5517931B2 (en) 2007-06-29 2014-06-11 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド Analysis of amino acids in body fluids by liquid chromatography mass spectrometry EP2194066B1 (en) 2007-09-26 2016-03-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR MX2010003329A (en) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anti-il-6 receptor antibody. CA2700986A1 (en) 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects BRPI0911431B8 (en) 2008-04-11 2021-05-25 Chugai Pharmaceutical Co Ltd pharmaceutical composition comprising an antigen and method of increasing the number of antigens that can be bound by an antibody AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use JP2011524204A (en) 2008-06-14 2011-09-01 バイトロナス， インコーポレイテッド System and method for delivering energy to tissue DK2328616T3 (en) 2008-08-05 2015-07-20 Novartis Ag Compositions and Methods for Antibodies to Complement Protein C5 TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders WO2010098863A1 (en) 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates KR20120105405A (en) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 Bispecific antibodies that bind to complement proteins CN101875696B (en) * 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 Antibody, and preparation method and application thereof EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity EP2528948B1 (en) 2010-01-28 2018-09-19 AB Biosciences, Inc. Novel lowered affinity antibodies and methods of making the same ES2615732T3 (en) 2010-03-01 2017-06-08 Alexion Pharmaceuticals, Inc. Compositions to treat Degos disease TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding CN105218674A (en) 2010-03-11 2016-01-06 瑞纳神经科学公司 The antibody combined in pH dependence antigen TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance CN103108885A (en) 2010-04-30 2013-05-15 阿雷克森制药公司 Antibodies having reduced immunogenicity in a human JP6030452B2 (en) 2010-11-30 2016-11-24 中外製薬株式会社 Antigen-binding molecules that repeatedly bind to multiple molecules of antigen CA2822288A1 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments KR20230005405A (en) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody BR122016016837A2 (en) 2011-05-21 2019-08-27 Macrogenics Inc cd3 binding molecules; cd3 binding antibodies; pharmaceutical compositions; and uses of the cd3 binding molecule EP2720708A4 (en) * 2011-06-20 2015-10-14 Univ Saint Louis TARGETING NEUROMUSCULAR JUNCTION FOR TREATMENT WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance JP6271251B2 (en) 2011-10-05 2018-01-31 中外製薬株式会社 An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex KR102219987B1 (en) 2012-02-24 2021-02-25 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB CN104302171B (en) 2012-03-16 2017-05-03 瑞泽恩制药公司 Non-human animals expressing PH-sensitive immunoglobulin sequences US9334334B2 (en) * 2012-03-16 2016-05-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same CA2869048C (en) * 2012-03-29 2023-10-17 Novimmune S.A. Anti-tlr4 antibodies and uses thereof TWI619729B (en) 2012-04-02 2018-04-01 再生元醫藥公司 Anti-hla-b*27 antibodies and uses thereof EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens MX363213B (en) * 2012-08-13 2019-03-15 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics. US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5 TW201418707A (en) * 2012-09-21 2014-05-16 Alexion Pharma Inc Screening assays for complement component C5 antagonists RU2663349C2 (en) * 2013-01-31 2018-08-03 СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН C5 antibody and method for preventing and treating complement-related diseases US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete EP2968985A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 CN105246914B (en) 2013-04-02 2021-08-27 中外制药株式会社 Fc region variants WO2015023972A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant JP6382641B2 (en) 2013-09-11 2018-08-29 株式会社東芝 Nonaqueous electrolyte battery and method for producing nonaqueous electrolyte battery RU2693430C2 (en) 2014-02-20 2019-07-02 Аллерган, Инк. Antibodies to complement component c5 NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics JP2016024424A (en) 2014-07-24 2016-02-08 株式会社リコー Information processing system, information processing device, information processing method, and program CA2967554A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-c5 antibodies and methods of use WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use TW202248212A (en) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof RU2730590C2 (en) 2015-02-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Composition for treating diseases associated with il-6 JP6944375B2 (en) 2015-03-31 2021-10-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド Identification and treatment of a subpopulation of patients with paroxysmal nocturnal hemoglobinuria (PNH) US20180311299A1 (en) 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant WO2016209956A1 (en) 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant TW201718014A (en) 2015-10-12 2017-06-01 諾華公司 Use of C5 inhibitors in Transplant Associated Microangiopathy PL3390442T3 (en) 2015-12-18 2024-03-18 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent WO2017123636A1 (en) 2016-01-11 2017-07-20 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment US20190085095A1 (en) 2016-01-25 2019-03-21 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch SG10202012243VA (en) 2016-06-14 2021-01-28 Regeneron Pharma Anti-c5 antibodies and uses thereof CA3021956A1 (en) 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use MX2019007749A (en) 2017-01-31 2019-09-09 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease. BR112019019108A2 (en) 2017-03-14 2020-04-22 Five Prime Therapeutics, Inc. antibodies, nucleic acid, compositions, cell, methods for preparing an antibody, to treat a subject with cancer, to treat an infectious disease, to treat an inflammation, to identify an ab, to improve an ab's anti-tumor efficacy, to improve the pharmacokinetics of an antibody, for selection of an antibody, to improve the effectiveness of antibodies, to isolate antibodies and to detect sight in a sample TWI788332B (en) 2017-03-16 2023-01-01 英商梅迪繆思有限公司 Anti-par2 antibodies and uses thereof JP7486415B2 (en) 2017-04-03 2024-05-17 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Treatment of inflammatory diseases with inhibitors of C5a activity CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) KR20200095485A (en) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 Regulators of complement activity WO2020027279A1 (en) 2018-08-01 2020-02-06 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease